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Abstract
It is well established that HIV antiretroviral drugs, particularly protease inhibitors, frequently elicit
a metabolic syndrome that may include hyperlipidemia, lipodystrophy, and insulin resistance.
Metabolic dysfunction in non-HIV-infected subjects has been repeatedly associated with cognitive
impairment in epidemiological and experimental studies, but it is not yet understood if
antiretroviral therapy-induced metabolic syndrome might contribute to HIV-associated neurologic
decline. To determine if protease inhibitor-induced metabolic dysfunction in mice is accompanied
by adverse neurologic effects, C57BL/6 mice were given combined lopinavir/ritonavir (50/12.5 to
200/50 mg/kg) daily for 3 weeks. Data show that lopinavir/ritonavir administration caused
significant metabolic derangement, including alterations in body weight and fat mass, as well as
dose-dependent patterns of hyperlipidemia, hypoadiponectinemia, hypoleptinemia, and
hyperinsulinemia. Evaluation of neurologic function revealed that even the lowest dose of
lopinavir/ritonavir caused significant cognitive impairment assessed in multi-unit T-maze, but did
not affect motoric functions assessed as rotarod performance. Collectively, our results indicate that
repeated lopinavir/ritonavir administration produces cognitive as well as metabolic impairments,
and suggest that the development of selective aspects of metabolic syndrome in HIV patients
could contribute to HIV-associated neurocognitive disorders.
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1. INTRODUCTION
In the US and other developed nations, survival rates associated with HIV infection have
improved dramatically since the introduction of combination antiretroviral therapies (ART),
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which act to restrict viral replication, and accordingly raise CD4 cell counts, prevent
opportunistic infections, and improve and extend health-related quality of life (reviewed by
Quinn, 2008). Indeed, the advent of ART has revolutionized the care of HIV-positive
patients, triggering an evolution from palliative, end-of-life care to long-term clinical
management of chronic infection. ART elements can currently be divided into five major
drug classes: protease inhibitors (PIs; including ritonavir, lopinavir, and tipranavir),
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs), and the emerging entry and integrase inhibitors.
Despite the unquestionable life-saving effects of ART, epidemiological data have revealed
significant iatrogenic metabolic complications of these drugs. These metabolic disturbances
produce clinical syndromes that can include dyslipidemia, insulin resistance, and
lipodystrophy (reviewed by Herman and Easterbrook, 2001; Anuurad et al., 2009), which
not only affect patient health, but also limit ART compliance (reviewed by Schambelan et
al., 2002). Although multiple factors influence metabolism in HIV patients, exposure to PIs
is thought to play a major and specific role in the development of dyslipidemia, as PIs are
well-known to profoundly affect serum and hepatic triglycerides, body fat composition, and
adipokine levels both in humans and mice (Lenhard et al., 2000a,b,c; Tsiodras et al., 2000;
Prot et al., 2006; Moyle, 2007; Thomas and Smart, 2007; Jiang et al., 2009).
While the widespread availability of ART has lead to remarkable improvements in immune
health outcomes, HIV-associated neurologic disorders remain a significant public health
concern. HIV-associated neurocognitive disorders (HAND), AIDS dementia complex,
HIV-1 associated cognitive-motor complex, and (collectively termed neuroAIDS) are all
neurological syndromes that can occur in conjunction with HIV infection (reviewed in
Ances and Ellis, 2007; Nath et al., 2008; Power et al, 2009). While the incidence of the most
severe forms of neuroAIDS (e.g., AIDS dementia complex) have significantly declined in
the era of ART (Sacktor et al., 2001), the incidence and prevalence of milder forms of
neuroAIDS (e.g., HAND) have been relatively stable (McArthur, 2004) and may have even
increased with widespread ART utilization (McArthur et al., 2003). While some ART drugs,
including the non-nucleoside analog efavirenz, are more strongly associated with adverse
neurologic side effects (Cespedes and Aberg, 2006) and could perhaps have direct CNS
effects, most studies suggest that better neurologic outcomes can be achieved by ART
elements with higher degrees of CNS penetration (De Luca et al., 2002; Patel et al., 2006).
Thus, the profile of neuroAIDS in the United States has changed significantly in response to
the widespread availability of ART, and new physiologic issues (potentially including
metabolic disturbances) likely participate in the sequelae of HAND in the ART era. Indeed,
emerging epidemiological and experimental studies clearly demonstrate that metabolic
dysfunction increases brain pathogenesis and decreases cognitive function (reviewed by
Bruce-Keller et al., 2009). Furthermore, recent reports indicate that HIV patients with
metabolic compromise may have a significantly greater risk of developing neurologic
complications, including both cognitive and motor disturbances (Valcour et al., 2004, 2005,
2006, 2008; Bandaru et al., 2007). While the adverse metabolic effects of ART on
atherosclerosis and cardiovascular risk are well known, effects of ART on neurologic
function have not been directly examined. Thus, these studies were undertaken to determine
the ability of ART-induced metabolic dysfunction to disrupt brain function in experimental
animals. To this end, C57BL/6 mice were given lopinavir/ritonavir daily for 3 weeks, and
then tested for both metabolic and neurologic function.
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2. MATERIALS AND METHODS
2.1 Animal Treatments
The Institutional Animal Care and Use Committee at the Pennington Center approved all
experimental protocols, which were compliant with NIH guidelines on the use of
experimental animals. 12 month-old male C57Bl/6NIA mice were purchased from the
National Institute on Aging contract facility maintained by Charles River Laboratories
(Wilmimgton, MA). All mice were housed in standard cages with 12:12 light: dark cycle,
and had ad libitum access to food and water throughout the study. Lopinavir/ritonavir (oral
Kaletra, Abbott Laboratories), was diluted in a vehicle of 10% ethanol/15% propylene
glycol, and mice received daily intraperitoneal injections of vehicle or lopinavir/ritonavir at
50/12.5, 100/25, and 200/50 mg/kg. This dose range was based on dosing guidelines for
daily oral lopinavir/ritonavir in adult HIV patients (800/200 total mg or 10/2.5 mg/kg), and
on body surface area (BSA) normalization factors (Pinkel, 1958; Sawyer and Ratain, 2001;
Reagan-Shaw et al., 2007), which translates 10 mg/kg in humans to approximately 125 mg/
kg in mice.
Body weight, body composition, food intake, and blood glucose of all mice were measured
regularly throughout the duration of exposure. Food intake was calculated by regularly
weighing the amount of food given to mice and calculating the daily loss. Body composition
was measured using a Bruker minispec LF90 time domain NMR analyzer (Bruker Optics,
Billerica MA). Glucose was measured in blood collected by tail nick using a glucometer
(Ascensia Elite, Bayer, Mishawaka, IN).
All blood samples were taken after a brief (6 hr) fast. After behavioral testing, all mice were
humanely euthanatized, and trunk blood, brain, and adipose tissue were collected. Data were
compiled from 2 separate cohorts of mice, with a total of 9–20 animals in each group.
2.2 UPLC-MRM-MS measures of lopinavir concentrations in serum and brain
Liponavir concentrations in serum and brain tissue were quantified using reverse phase ultra
performance liquid chromatography-multiple reaction monitoring -mass spectrometry
(UPLC-MRM-MS). Serum and brain homogenates (12 mg/ml) were defrosted at 4ºC,
deproteinized by adding chilled methanol (4x volume) and incubated at −20 ºC for 1h.
Samples were centrifuged (20,800 g, 15 min, 4 ºC) and supernatants were evaporated to
dryness. Samples were resuspended in a solvent containing 80% water, 20% acetonitrile and
0.1% formic acid. Reverse phase UPLC separations were conducted using a flow rate of 0.6
mL/min with 0.1% formic acid as mobile phase A and 100% acetonitrile in 0.1% formic
acid as mobile phase B. Samples were injected on a BEH C18 column (1.7 μm, 2.1 × 50
mm, Waters Corp.) and eluted with a linear gradient of 20–97% mobile phase B in 5 min.
All samples were analyzed in triplicate. Samples eluted from the chromatographic column
were ionized by the electrospray ionization (ESI) source and analyzed by the triple
quadrupole mass spectrometer (XEVO TQMS, Waters Corp.) The mass spectrometer was
operated in positive ion mode, with an electrospray voltage of 4 kV, cone voltage of 22 V,
extraction cone voltage of 3 V, source temperature 150 °C and desolvation temperature of
600 °C. The mass/charge range was monitored for four MRM transitions (precursor to
fragment ion transitions) 629.5/155.1, 629.5/120.1, 629.5/183.1 and 629.5/447.3 and the
cycle (dwell time of 25 ms for each MRM transition) was repeated for the entire
chromatographic gradient. The optimal collision energy for the four transitions listed above
was 50, 38, 22 and 14, respectively. Calibration standards were generated by spiking mouse
blood serum and brain homogenates with lopinavir. Standard calibration curves were
generated using 1/X-weighted linear regressions and used to determine lopinavir
concentration in samples. TargetLynx (Waters Corp.) was used for data processing.
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2.2 Behavioral analysis of cognitive performance: Stone T-maze
Cognitive ability was tested behaviorally on all mice using the five-segmented, Stone T-
maze as described in previously published reports (Pistell et al., 2009; Pistell and Ingram,
2010). Briefly, performance in this maze requires the mouse to learn the correct sequence of
13 consecutive left and right turns to reach the goal box and successfully escape the maze.
Mice are motivated to escape because they are required to wade (not swim) through the
maze, as the apparatus is maintained in a tray of water (21–23 °C) filled to a level (1.5 cm)
that allows the mice to keep their head out of the water while maintaining contact with the
floor, but the height of the maze prevents rearing. The day before acquisition testing, all
animals were pre-trained to escape the water using a straight runway constructed of acrylic
with opaque sides. For acquisition testing, mice were given 15 sequential trials in the T-
maze in a single day. Mice were tested in groups of 8–10 mice, and were run through such
that the first trial was completed by all mice before proceeding to the second trial, insuring
that each mouse had sufficient rest between trials to prevent any potential effects of fatigue.
Trials were recorded using video tracking software (Viewpoint Lifesciences, Inc), and the
latency to reach the goal box, and the numbers of errors committed were recorded and used
as the primary measure of learning because it is unbiased by potential confounds resulting
from differences in motor function. For the purpose of data analysis and presentation, maze
acquisition data was collapsed into 5 separate blocks of 3 trials each.
2.3 Behavioral analysis of motor performance: Rotarod
Motor function was analyzed using a Five Station Rota-Rod Treadmill for Mouse (Med-
Associates, St. Albans, VT). Each mouse was given three trials during which the starting
speed of the rotarod was 4 rpm, but the rod accelerated to 40 rpm over a period of five min.
The amount of time the animal was able to remain on an accelerating rotating cylinder was
recorded and used as the primary measure of motor function. The maximum trial length was
5 min and there was a 30 min rest period between each trial.
2.4 Clinical Chemistry
Trunk blood was allowed to clot at 4ºC overnight and then centrifuged at 3000×g for 30
minutes, and serum collected and either analyzed immediately or stored at −80ºC. Levels of
total cholesterol, triglycerides, and nonesterified fatty acids (NEFA) in sera were measured
colorimetrically using commercially available kits (Wako Chemicals, Richmond, VA).
Adiponectin, leptin, and insulin levels in serum were all evaluated by ELISA in accordance
with the Manufacturer’s assay protocol (R&D Systems, Minneapolis, MN for adiponectin
and leptin; and Crystal Chem Inc., Downers Grove IL for insulin) and read on a Victor plate
reader (Perkin Elmer, Waltham, MA) set at 450nm with wavelength correction at 540nm.
2.5 Statistical analyses
All data are shown as mean ± standard error of measurement. Body weight, body
composition, food intake, and blood glucose levels were analyzed with 2-way, repeated
measures analyses of variance (ANOVA) to determine main effects of treatment group and
duration, followed by Bonferroni post-hoc comparisons to determine differences between
lopinavir/ritonavir and vehicle groups. Stone maze performance was also analyzed with 2-
way repeated measures ANOVA to determine main effects of trail block and treatment,
again followed by Bonferroni post-hoc comparisons to determine differences between
lopinavir/ritonavir and vehicle groups. Rotarod, glucose, serum lipid, and serum hormone
data were analyzed by 1-way ANOVA to determine group differences, followed by Tukey’s
post-hoc analyses to determine specific differences between lopinavir/ritonavir and vehicle
groups. Statistical significance for all analyses was accepted at p < 0.05, and *, **, and ***
represent p < 0.05, p < 0.01, and p < 0.001, respectively.
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3. RESULTS
3.1 Effects of lopinavir/ritonavir on body weight and composition
The PI class of antiretroviral drug is most frequently associated with severe metabolic
abnormalities both in humans and in mice (Lenhard 2000a,b,c; Tsiodras et al., 2000;
Hurwitz et al., 2004; Prot et al., 2006; Moyle, 2007), and thus these studies were designed to
evaluate the ability of PIs to disrupt neurologic as well as metabolic function. Combined
lopinavir/ritonavir (Kaletra, Abbott Laboratories, Abbott Park, IL) is a cocktail prepared at a
4:1 ratio, and this specific drug was selected as it is both very commonly used in clinical
settings to manage HIV (reviewed in Cvetkovic and Goa, 2003), and also has a strong
association with metabolic derangement both in humans and in mice (Prot et al., 2006;
Chandwani and Shuter, 2008). Dosing guidelines for oral lopinavir/ritonavir in adult HIV
patients prescribe 10mls (or 800/200 mg) per day, which is approximately 10/2.5 mg/kg for
an average 80 kg (175 lb) male. The calculation to accurately translate human to animal
doses requires correction for body surface area (BSA) normalization (Reagan-Shaw et al.,
2007), and dose translation calculations equate 10 mg/kg in humans to approximately 125
mg/kg in mice (data not shown). To confirm the accuracy of BSA calculations,
concentrations of lopinavir were measured in the serum of mice exactly 4 hours after
intraperitoneal injection of either 100 gm lopinavir/25 mg ritonavir/kg or 50/12.5 mg/kg,
using UPLC-MRM-MS as described in Methods (Table 1). These data show that serum
levels of lopinavir in this study approximate clinical levels, as Kaletra is reported by the
drug Manufacturer (Abbott) to have a Cmax for lopinavir of 9.8 + 3.7 ug/ml approximately 4
hours after administration to adult HIV-positive patients. Additionally, UPLC-MRM-MS
techniques were also used to measure lopinavir in the brains of mice treated acutely and
euthanized exactly 4 hours after injection, and show that levels of lopinavir in brain were
nearly 200-fold lower than levels in serum (Table 1). Finally, brain levels of lopinavir were
measured 24 hours after injection in mice treated daily with lopinavir/ritonavir for 21 days.
These data show that brain lopinavir levels fall precipitously (by 10–20 fold) 24 hours after
injection, and accordingly do not indicate that lopinavir accumulates in the brain following
repeated daily administration.
Twelve-month old C57BL/6 mice were then administered a 21-day regimen of daily
intraperitoneal injections of either vehicle (10% ethanol/15% propylene glycol) or low,
medium, or high doses of lopinavir/ritonavir (50/12.5, 100/25, or 200/50 mg/kg body
weight). Overall body weight was recorded regularly as an index of overall health of the
mice and to ensure that the mice were not made severely ill (cachexic) by the drugs, and
indeed high doses (200/50 mg/kg) of PI produced severe weight loss (> 20% of body
weight, data not shown), and thus these higher doses were discontinued and not studied
further. Statistical evaluation of the effects of low and medium doses of PI on body weight
by repeated measures ANOVA revealed a significant main effect of treatment duration on
body weight (F(2,44) = 58.81, p < 0.0001), but there was no significant effect of drug
administration on body weight (F(2,44) = 1.512, p = 0.2317). However, there was a
statistically significant interaction of treatment and drug (F(2,44) = 14.68, p < 0.0001), and
post-hoc tests revealed that only the 100/25 mg/kg lopinavir/ritonavir caused significant
weight loss, and only when measured at the end of exposure (Fig. 1A). Mice were also
evaluated for body composition using NMR as described in Methods, and data show
significant loss of fat mass in mice treated with either 50/12.5 or 100/25 mg/kg lopinavir/
ritonavir (Fig. 1B). Specifically, 2-way ANOVA revealed significant main effects of
duration (F(2,43) = 27.28, p < 0.0001) and treatment group (F(2,43) = 720.95, p < 0.0001), on
fat composition, with also a significant interaction (F(2,43) = 5.975, p = 0.0003). Post-hoc
analyses revealed significant decreases in body fat caused by both 50/12.5 and 100/25 mg/
kg lopinavir/ritonavir when measured at either 10 or 20 days after treatment onset (Fig. 1B).
To evaluate the loss of body and fat weight in these mice, food intake over the duration of
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treatment was measured (Fig. 1C), and data analyses revealed a significant main effect of
treatment duration (F(2,15) = 17.78, p < 0.0001) and drug administration (F(2,15) = 11.28, p =
0.001), on food intake, with also a significant interaction (F(2,15) = 14.41, p < 0.0001). Post-
hoc analysis of food intake data revealed that only the 100/25 mg/kg dose of lopinavir/
ritonavir decreased food intake, and only after 20 days of treatment (Fig. C). These data
indicate that the low dose of lopinavir/ritonavir administration reproduces a pattern of
lipodystrophy in mice similar to that observed in human subjects prescribed PI, but that
higher doses also cause significant weight loss that is likely compounded by decreased food
intake.
3.2 Effects of lopinavir/ritonavir on cognitive and motor performance
To determine if PI-induced metabolic compromise was associated with neurologic
impairment, both motor and cognitive functions were assessed. To ensure that the behavioral
data reflected only the most direct effects of the PI drugs and were not confounded
artificially by metabolic changes secondary to decreased food intake, only vehicle- and
50/12.5 mg/kg lopinavir/ritonavir-treated mice were included in behavioral analyses.
Cognitive function was measured using the Stone T-maze maze after 3 weeks of lopinavir/
ritonavir exposure. The Stone maze is a task of procedural learning and memory has been
used to evaluate cognitive impairments in rodents (Stranahan et al., 2008; Shukitt-Hale et
al., 2008; Pistell et al., 2009, Pistell and Ingram, 2010). Furthermore, this task is very well
suited for use in mice as it does not require the animals to swim, and is not confounded by
changes in nociception, food-seeking behavior, or motor impairment (Pistell et al., 2010).
By recording errors made across 15 training trials in this task, we observed that lopinavir/
ritonavir treatment resulted in significant cognitive impairment (Fig 2A). Specifically,
ANOVA on errors committed by mice revealed significant main effects of trial number
(F(4, 25) = 47.66, p < 0.0001) and treatment group (F(1,25) = 9.817, p = 0.0044), with also a
significant interaction (F(4,25) = 3.361, p = 0.0126). Post-hoc analyses revealed that 50/12.5
mg/kg lopinavir/ritonavir-treated mice committed significantly more errors in the trial
blocks 4–6, 7–9, and 10–12 as compared to vehicle-treated mice (Fig. 2A). The degree of
impairment caused by lopinavir/ritonavir (approximately 70% increase in errors in trials 4–
12) is greater than the degree of impairment caused by diet-induced obesity in mice (Pistell
et al., 2010), but is roughly comparable to the degree of cognitive impairment noted in aged
(25 month) mice compared to young (5-month) mice (D.K. Ingram and P.J. Pistell,
unpublished observations). Finally, although naïve (i.e., not injected) mice were not
included in this specific study, comparison of data obtained from vehicle-injected mice to
published data obtained from control, un-manipulated C57BL/6 mice of the same age
(Pistell and Ingram, 2010) does not suggest that the regimen of daily injections significantly
affected Stone maze performance in vehicle-treated mice.
The rotarod is a very commonly used task for assessing motor ability in rodents, and
measures the time the animal is able to remain on an accelerating rotating cylinder. Motor
performance of vehicle- and 50/12.5 mg/kg lopinavir/ritonavir-treated mice was thus
analyzed using the rotarod after 3 weeks of lopinavir/ritonavir exposure as described in
Methods. Analysis of rotarod performance data did not reveal any impairment in motor
function in 50/12.5 mg/kg lopinavir/ritonavir-treated mice as compared to vehicle-treated
mice (Fig 2B).
3.3 Effects of lopinavir/ritonavir on metabolic parameters
As the PI drugs themselves are not blood-brain barrier permeable, aspects of metabolic
syndrome were examined to begin to understand how administration of PI drugs disrupts
cognition. To confirm that NMR-based measures of body composition indicated significant
lipoatrophy, the retroperitoneal fat pad was isolated from all mice and weighed. Data show
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that lopinavir/ritonavir treatment caused significant differences in retroperitoneal fat pad
mass between groups (F(43) = 31.08, p < 0.0001), and post-hoc analyses confirmed
significant dose-dependent lipodystrophic effects of lopinavir/ritonavir (Fig. 3A). In addition
to its function as an energy store, adipose tissue is well known to be an important player in
the regulation of many biological processes through the secretion of adipokines (Frühbeck,
2008;Rocha and Libby, 2008). Over 50 adipokines have been identified, and generally
function as hormones to influence energy homeostasis and feeding behavior (Ahima and
Osei, 2008). However, certain adipokines, particularly adiponectin and leptin have been
shown to have potentially important physiological effects in the brain (Harvey et al.,
2005;Oomura et al., 2006;Harvey, 2007;Ouchi and Walsh, 2007;Chen et al., 2009). To thus
determine if PI-induced loss of adipose tissue was associated with decreased circulating
adipokines, levels of adiponectin and leptin were measured in vehicle- and lopinavir/
ritonavir-treated mice. Data show that lopinavir/ritonavir treatment caused significant
decreases in circulating leptin (F(38) = 19.81, p < 0.0001; Fig. 3B) and adiponectin (F(40) =
36.98, p < 0.0001; Fig. 3C). Post-hoc analyses also revealed significant, dose-dependent
effects of both 50 and 100 mg/kg doses of lopinavir/ritonavir on serum adipokines.
Lipodystrophy is also associated with dyslipidemia as adipose tissue serves as the normal
repository for lipid storage, and adipose tissue loss leads to elevations in the circulation and
tissue deposition of blood lipids (Heilbronn et al., 2004; Simha and Gang, 2009). Indeed,
one of the most common and rapid effects of PI therapy in humans is significant
hyperlipidemia, with specific increases in triglycerides, fatty acids, and cholesterol (Tsiodras
et al., 2000; Green, 2002; Moyle, 2007). As these lipid mediators are associated with
neurologic impairment in non HIV-infected individuals, studies next assessed the panel of
bioactive serum lipids in lopinavir/ritonavir-treated mice. Data show that the 21 day
lopinavir/ritonavir regimen caused significant alterations in total serum cholesterol (Fig.
4A), as well as triglycerides (Fig. 4B) and fatty acids (NEFA, Fig. 4C). Statistical analyses
confirm significant differences between treatment groups in circulating cholesterol (F(43) =
5.225, p = 0.0095), triglycerides (F(36) = 5.386, p = 0.0093), and fatty acids (F(38) = 3.98, p
= 0.0275). However, post-hoc analyses revealed that only triglycerides were significantly
elevated by the low 50 mg/kg dose of lopinavir/ritonavir (Fig. 4B).
To determine if the PI-induced pattern of lipodystrophy and hyperlipidemia was associated
with loss of glycemic control, blood glucose was measured throughout the duration of PI
exposure, and insulin levels in serum were measured after 3 weeks of exposure. Data show
that fasting blood glucose was not significantly altered at any time during exposure to daily
lopinavir/ritonavir administration (Fig. 5A). However, data show that lopinavir/ritonavir did
cause significant changes in serum insulin levels measured after the 21-day regimen (Fig.
5B). The 1-way ANOVA indicated significant differences in serum insulin between
groups(F(23) = 4.13, p = 0.0307), but post-hoc analyses showed that only the 100 mg/kg
dose significantly elevated insulin levels (Fig. 5B).
4. DISCUSSION
While HIV-1 most directly targets the host immune system, many HIV-infected individuals
also exhibit a spectrum of neurologic disorders ranging from peripheral neuropathy to mild
behavioral disturbances to overt dementia (reviewed in Ances and Ellis, 2007; Nath et al.,
2008; Power et al., 2009). While estimates of the prevalence of dementia in the early 1990’s
approached 30%, the widespread availability of combination ART has dramatically reduced
the most severe forms of HIV-associated dementia (Sacktor et al., 2001). However, HIV
remains the most common preventable and treatable cause of neurologic impairment in
patients under 50 (Ances and Ellis, 2007), and epidemiological data suggest that the
prevalence of HIV-associated neurocognitive disorders (HAND) have not been significantly
Pistell et al. Page 7
Antiviral Res. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
reduced by ART intervention (McArthur et al., 2003; McArthur, 2004). For example,
epidemiological evidence suggests that while only approximately ~10% of HIV-positive
suffer from HIV-associated dementia, near 30% of HIV-1-positive individuals display more
subtle manifestations of neurologic dysfunction (McArthur et al., 2003). As ART regimens
are generally quite capable of maintaining low viral load, these data indicate that new
mediators of neurologic dysfunction may have developed in the ART era. The results
emerging from our study indicate that ART elements themselves, acting through the
development of specific aspects of metabolic dysfunction, could be indirectly contributing to
neurologic abnormalities in HIV-positive patients. While it is recognized that the metabolic
effects of ART could contribute to premature atherosclerosis and cardiovascular risk in HIV
patients, the potential effects of dyslipidemia on neurologic function in HIV patients have
not been directly examined. However, recent reports indicate that HIV patients with
metabolic compromise have a significantly greater risk of developing neurologic
complications, including both cognitive and motor disturbances (Valcour et al., 2004, 2005,
2006, 2008). Collectively, available data show that ART can cause metabolic syndrome and
in turn suggest that metabolic syndrome may participate in the development of neurologic
and cognitive dysfunction.
While the exact physiologic mechanisms whereby ART-induced metabolic changes could
alter cognition are not known, one of the most significant and early changes noted in this
study of lopinavir/ritonavir-treated mice was the rapid and significant decline in total fat
mass. This observation is in keeping with clinical observations of HIV patients, as the HIV
FRAM study revealed that HIV-infected men with lipoatrophy had less peripheral and
central subcutaneous adipose tissue (SAT) and also less visceral adipose tissue (VAT)
(Bacchetti et al., 2005), contrary to the early impression that peripheral lipoatrophy is
always accompanied by central fat accumulation. Although protease inhibitors are thought
to participate in ART-related disruptions to adipose (reviewed in Flint et al., 2009), the
development of lipodystrophy is also associated with nucleoside reverse transcriptase
inhibitors (NRTIs) particularly stavudine and zidovudine, which are well known to disrupt
adipose physiology via the induction of mitochondrial dysfunction (Villaroya et al., 2005;
Caron-Debarle et al., 2010). While the nature of the link between lipoatrophy and brain
function has not been well studied, it is becoming understood that adipose tissue is an
important factor in the regulation of many pathological processes via the secretion of
adipokines (Frühbeck, 2008; Rocha and Libby, 2008; Ahima and Osei, 2008). Data in this
manuscript show that the adipokines adiponectin and leptin were significantly and dose-
dependently reduced by lopinavir/ritonavir treatment, and these specific adipose-released
signals have been shown to have potentially important physiological effects in the brain
(Harvey et al., 2005; Oomura et al., 2006; Harvey, 2007; Ouchi and Walsh, 2007; Chen et
al;, 2009). While leptin is best known as an afferent adiposity signal to the brain that
suppresses appetite and increases energy expenditure (Friedman and Halaas, 1998), leptin
receptors (OBR) are widely expressed in numerous extra-hypothalamic regions of the brain,
including the hippocampus, cerebellum, amygdala, and brain stem (Elmquist et al., 1998;
Tartaglia et al., 1995; Fei et al., 1997). Studies have also identified a role for leptin in
cognitive processes (reviewed in Harvey et al., 2005; White et al., 2009). For example,
direct administration of leptin into the dentate gyrus has been shown to enhance long term
potentiation (Wayner et al., 2004), and intravenous administration of leptin can facilitate the
behavioral performance of rats in passive avoidance and Morris water-maze tasks (Oomura
et al., 2006). Finally, leptin has been shown to modulate inflammatory signaling in microglia
(Pinteaux et al., 2007; Tang et al., 2007) which could affect brain inflammatory and
oxidative pathways. Likewise, adiponectin is significantly decreased in HIV-positive
patients with lipodystrophy (Kinlaw and Marsh, 2004; Barbaro, 2007), and has well-known
anti-inflammatory affects (Ouchi and Walsh, 2007 that have been shown to be
neuroprotective (Jung et al., 2006; Chen et al., 2009).
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Lipodystrophy can also lead to significant disruption in the circulation and tissue deposition
of blood lipids (Heilbronn et al., 2004; Simha and Garg, 2008). Indeed, one of the most
common and rapid effects of PI therapy in humans is significant hyperlipidemia, with
specific increases in triglycerides, fatty acids, and cholesterol (Tsiodras et al;, 2000; Green,
2002; Moyle, 2007). Data presented in this manuscript show that combined lopinavir/
ritonavir treatment reproduces this pattern of hyperlipidemia in mice. However, it is not
clear whether lopinavir or ritonavir, or the combination of both, is ultimately responsible for
triggering the chain of events leading to metabolic and cognitive dysfunction. Ritonavir is
included in ART formulations not for its own antiviral activity, but because it profoundly
boosts the action of other PIs via inhibition of hepatic cytochrome P450-3A4 activity (Merry
et al., 1997). Indeed, this discovery has led to dramatic improvements in PI efficacy, but also
has resulted in adverse effects related to altered metabolism of medications and/or food
additives. Thus, it is possible that ritonavir could have disrupted metabolism of the ethanol
and propylene glycol components of the vehicle, or even altered bile acid metabolism
(Bodin et al., 2005), leading to alterations in the metabolism of dietary lipids. While
elevated serum lipids might disrupt cognitive function directly via disruptions to
cerebrovascular perfusion, many studies have examined the role of serum cholesterol in
brain function independent of vascular effects. In general, results are mixed, with some
studies noting a correlation between cholesterol levels and cognitive function, whereas other
studies do not (Reitz et al., 2005; Rogers et al., 1989; Atzmon et al., 2002).
Alternatively, hypertriglyceridemia is perhaps the most frequent and severe metabolic
manifestation of PI therapy in humans (Tsiodras et al., 2000; Green, 2002; Moyle, 2007),
and data reported in this manuscript shows that triglycerides and fatty acids were increased
by lopinavir/ritonavir to a greater degree than cholesterol. Furthermore, triglycerides were
significantly increased by the low dose of lopinavir/ritonavir that also affected cognition,
while higher doses of lopinavir/ritonavir were necessary to increase cholesterol and insulin
levels significantly over levels in vehicle-treated mice. Triglycerides and free fatty acids are
well known to initiate toxic, oxidant-based signaling in the vascular endothelium (Hennig et
al., 2001), but interestingly, there is compelling evidence that triglycerides and/or free fatty
acids might mediate CNS dysfunction. For example, it has been shown that direct
administration of triglycerides can impair hippocampal long-term potentiation, and that
lowering triglycerides pharmacologically with gemfibrozil reduces the expression of
markers of oxidative stress in the brains of obese mice (Farr et al., 2008). These studies are
further supported by clinical studies in which it has been shown that elevated triglycerides
are associated with poor cognitive performance in patients with type 2 diabetes (Perlmuter et
al., 1998), and by studies in which the reduction of hypertriglyceridemia with gemfibrozil
improved cerebral blood flow and function on the cognitive capacity screening examination
(Rogers et al., 1989). Finally, triglycerides have been shown to impair leptin transport
through the blood-brain barrier (Banks et al., 2004), indicating that the well-characterized
phenomena of leptin resistance with age or obesity may be related in part to the action of
triglycerides at the blood-brain barrier. Another potential means whereby triglycerides could
adversely affect the brain is through their breakdown into free fatty acids, which can also be
formed and released directly from adipocytes in setting of lipoatrophy. GPR40, a putative
free fatty acid receptor, has been localized to the hippocampus (Ma et al., 2008), and the
saturated free fatty acids palmitic acid and lauric acid have both been shown to cause
inflammatory signaling in cultured macrophages (Laine et al., 2007; Aronis et al., 2008),
and also to modulate astrocytic and microglial signaling (Patil and Chan, 2005).
5. CONCLUSIONS
Our results confirm that lopinavir/ritonavir administration causes significant metabolic
dysfunction, including significant lipoatrophy and dose-dependent patterns of
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hypoadiponectinemia, hypoleptinemia, hyperlipidemia, and hyperinsulinemia. These data
are in keeping with published studies that have reported significant metabolic dysfunction in
C57BL/6 mice treated with combined lopinavir/ritonavir in similar dose ranges (Prot et al.,
2006). However, the most significant finding of this study is that even the lowest dose of
lopinavir/ritonavir caused significant cognitive impairment in mice. Thus, these data show
that HIV protease inhibitors can cause cognitive as well as metabolic impairment, and
suggest that the development metabolic dysfunction in HIV patients might contribute
significantly to HIV-associated neurocognitive decline. These data are consistent with a new
but growing body of literature describing the sensitivity of the brain to metabolic
dysfunction (reviewed in (Bruce-Keller et al., 2009). The relationship between metabolic
dysfunction and cognitive impairment has been documented in humans (Elias et al., 2003,
2005; Waldstein and Katzel, 2006), as well as in experimental animal studies (Baran et al.,
2005; Winocur and Greenwood, 2005; Granholm et al., 2008; White et al., 2009; Pistell et
al., 2010). Collectively, results from this study reinforce the link between metabolic
dysfunction and cognitive loss, and suggest that sustained metabolic dysfunction in HIV
patients could potentially participate in the pathogenesis of HAND.
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Figure 1. Lopinavir/ritonavir alters body weight and body composition in mice
Male C57BL/6 mice were treated daily with vehicle (open circles), 50 mg lopinavir/12.5 mg
ritonavir/kg (50 mg/kg L/R, closed triangles), or 100mg lopinavir/25 mg ritonavir/kg (100
mg/kg L/R, closed squares) and were evaluated regularly for (A) body weight; (B) total
body fat mass expressed as percent fat mass measured at day 0; and (C) food intake. All data
are mean and S.E.M. of 9–18 mice per group. Data were analyzed by 2-way ANOVA, and
*, **, and *** indicate significant (p<0.05, p<0.01, and p<0.001, respectively) differences
noted in lopinavir/ritonavir-treated mice as compared to vehicle-treated mice at the same
timepoint.
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Figure 2. Lopinavir/ritonavir disrupts cognitive but not motor ability in mice
Male C57BL/6 mice were treated daily with lopinavir/ritonavir (50mg lopinavir/12.5 mg
ritonavir/kg body weight) for 21 days and then tested behaviorally. (A) Effects of lopinavir/
ritonavir on the number of errors committed over 15 trials of maze training. Data are means
± S.E.M. of average errors accrued over 3-trial blocks and were generated from 9–18 mice
per group. Data were analyzed by 2-way ANOVA, and * indicates significant (p<0.05)
increases in errors made by lopinavir/ritonavir-treated mice. (C) Effects of lopinavir/
ritonavir on time mice were able to remain on an accelerating rotarod. Data are means ±
S.E.M. of average time on the rod measured over 3 trails.
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Figure 3. Lopinavir/ritonavir decreases retroperitoneal fat mass and circulating adipokines in
mice
Male C57BL/6 mice were treated daily with vehicle, 50 mg lopinavir/12.5 mg ritonavir/kg
(50 mg/kg L/R), or 100mg lopinavir/25 mg ritonavir/kg (100 mg/kg L/R). After 21 days,
mice were euthanatized and fat pads and sera were collected. (A) Effects of lopinavir/
ritonavir on the mass of the retroperitoneal fat pad. Data are means ± S.E.M. of fat pad mass
in milligrams, and were generated from 9–18 mice per group. Data were analyzed by 1-way
ANOVA, and *** indicates significant (p<0.001) decreases in mass in lopinavir/ritonavir-
treated mice as compared to vehicle-treated mice. (B) Effects of lopinavir/ritonavir on serum
leptin concentration. Data are means ± S.E.M. of leptin expressed as ng/ml serum, and were
generated from 9–18 mice per group. Data were analyzed by 1-way ANOVA, and ** and
*** indicate significant (p> 0.01 and p<0.001, respectively) decreases in leptin in lopinavir/
Pistell et al. Page 17
Antiviral Res. Author manuscript; available in PMC 2011 December 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
ritonavir-treated mice as compared to vehicle-treated mice. (C) Effects of lopinavir/ritonavir
on serum adiponectin concentration. Data are means ± S.E.M. of adiponectin expressed as
ng/μl serum, and were generated from 9–18 mice per group. Data were analyzed by 1-way
ANOVA, and *** indicates significant (p<0.001) decreases in adiponectin in lopinavir/
ritonavir-treated mice as compared to vehicle-treated mice.
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Figure 4. Lopinavir/ritonavir significantly increases circulating serum lipids in mice
Male C57BL/6 mice were treated daily with vehicle, 50 mg lopinavir/12.5 mg ritonavir/kg
(50 mg/kg L/R), or 100mg lopinavir/25 mg ritonavir/kg (100 mg/kg L/R). After 21 days,
mice were euthanatized and serum was collected. (A) Effects of lopinavir/ritonavir on total
serum cholesterol. Data are means ± S.E.M. of cholesterol expressed as mg/dl serum, and
were generated from 9–18 mice per group. Data were analyzed by 1-way ANOVA, and *
indicates a significant (p<0.05) increase in total cholesterol levels in mice treated with
100mg lopinavir/25 mg ritonavir/kg mice as compared to levels in vehicle-treated mice. (B)
Effects of lopinavir/ritonavir on serum triglyceride (TG) concentration. Data are means ±
S.E.M. of triglycerides expressed as mg/dl serum, and were generated from 9–18 mice per
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group. Data were analyzed by 1-way ANOVA, and * indicates significant (p> 0.05)
increases in triglycerides in lopinavir/ritonavir-treated mice as compared to vehicle-treated
mice. (C) Effects of lopinavir/ritonavir on serum fatty acids (NEFA). Data are means ±
S.E.M. of nonesterified fatty acids expressed as mEq/dl serum, and were generated from 9–
18 mice per group. Data were analyzed by 1-way ANOVA, and * indicates significant (p>
0.05) increases in serum fatty acids in lopinavir/ritonavir-treated mice as compared to
vehicle-treated mice.
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Figure 5. Lopinavir/ritonavir does not affect blood glucose in mice
(A) Male C57BL/6 mice were treated daily with vehicle (open circles), 50 mg lopinavir/12.5
mg ritonavir/kg (50 mg/kg L/R, closed triangles), or 100mg lopinavir/25 mg ritonavir/kg
(100 mg/kg L/R, closed squares) and were evaluated regularly for blood glucose as
described in Methods. Data are mean and S.E.M. of blood glucose expressed as mg/dl of
serum, and were generated from 9–18 mice per group. (B) Effects of lopinavir/ritonavir on
serum insulin. Male C57BL/6 mice were treated daily with vehicle, 50 mg lopinavir/12.5 mg
ritonavir/kg (50 mg/kg L/R), or 100mg lopinavir/25 mg ritonavir/kg (100 mg/kg L/R). After
21 days, mice were euthanatized and serum was collected, and insulin levels were
determined using ELISA as described in Methods. Data are means ± S.E.M. of insulin
expressed as ng/ml serum, and were generated from 9–18 mice per group. Data were
analyzed by 1-way ANOVA, and * indicates significant (p> 0.05) increases in serum insulin
in mice treated with 100mg lopinavir/25 mg ritonavir/kg as compared to vehicle-treated
mice.
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Table 1
Serum and brain lopinavir levels following injection
Male C57BL/6 mice were treated with increasing doses of combined lopinavir/ritonavir, and serum and brain
levels of lopinavir were measured by UPLC-MRM-MS exactly 4 hours after drug administration as described
in Methods. Lopinavir levels were also measured in brains of mice that had been treated daily with lopinavir/
ritonavir for 21 days, but had recovered for 24 following their last injection (Brain Lopinavir (24hs)). Data are
presented as μg lopinavir/ml serum and μg lopinavir/mg wet weight of brain, and are mean and STD of 2–4
mice per group.
Treatment Serum Lopinavir (μg/ml) Brain Lopinavir (μg/gm) Brain Lopinavir (24hs) (μg/gm)
100/25 mg/kg lopinavir/ritonavir 18.2 ± 1.0 0.109 ± 0.027 0.005 ± 0.001
50/12.5 mg/kg lopinavir/ritonavir 3.1 ± 0 .3 0.023 ± 0.002 0.002 ± 0.001
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